Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Discover how innovative physical therapy, smart medications, nutrition strategies and mind-body techniques are transforming ...

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

Study objective There is no consensus on the management of low back pain in the ED and evidence suggests that these patients are likely to receive unwarranted imaging and inappropriate opioid ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...